Novo Nordisk says lower insulin prices in China dent 2022 outlook

novo nordisk says lower insulin prices in china dent 2022 outlook

Sumary of Novo Nordisk says lower insulin prices in China dent 2022 outlook:

  • “By agreeing to lower prices for insulin in China, Novo now has to find out how they can sell more of their innovative products,” Sydbank analyst Soren Lontoft Hansen said, adding that Novo’s new forecast was a bit less negative than expected.
  • “It is not a very big sensation that the turnover in China is under pressure,” Nordnet analyst Per Hansen said in a note.

Want to know more click here go to source.

From -

Close
Generic selectors
Exact matches only
Search in title
Search in content

Site Language


By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close